UK based medical device company Platform-14 has successfully secured a CE mark for their new leading product - BioWave.
BioWave technology has been established in the US for over 13 years as a pain relief device, used in both professional and personal settings. The device, which has patented technology, uses high frequency conduction to block pain at the source. A published clinical trial of 428 patients demonstrated that 84% of patients experience a significant reduction in pain after using BioWave.
Chronic Pain affects more than two fifths of the UK population, meaning that around 28 million adults are living with pain that has lasted for three months or longer. The cause of Chronic Pain varies from patient to patient, however, the impact on mental health, earning potential and overall of quality of life are consistently reported consequences of the condition.
In April this year, the National Institute for Health and Care Excellence (NICE), the public body tasked with providing guidance over health technologies and clinical practices, issued new guidance for the management of Chronic Pain. The guidance offered no real solutions for patients living with Chronic Pain and effectively said that there was no support for them in the NHS.
The guidance has been met with widespread disapproval, and in May of this year, a group of expert clinicians and patient groups sent an open to letter to health secretary Matt Hancock calling for action from Government to help those living with pain.
In 2020, Platform 14 acquired a stake in BioWave USA and the securing of the CE mark means that BioWave will now be available on the Europe, the Middle East and Africa market.
Founder of Platform 14 Steve Dechan said: “We are delighted that BioWave has secured a CE mark and is now available for use in the UK. There are millions of adults living with Chronic Pain in the UK, with the NHS offering no solution for them beyond exercise and opioid pain relief. BioWave has the potential to revolutionise the chronic pain landscape, offering patients and the NHS a safe and effective drug-free solution.”
President elect of the World institute of Pain and Neuromodulation consultant, Dr Dominic Hegarty added: “Chronic Pain can be a debilitating and life changing condition. However, despite millions living with Chronic Pain throughout the UK, the condition is little understood and options for treatment for those living with pain are limited and often insufficient. BioWave is an effective, reliable and affordable pain therapy that has the potential to improve the lives of pain sufferers throughout the UK.”
